Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDK-003 in CTCL and Healthy Volunteers
NCT05156229Phase 1Terminated
- Sponsor
- Codiak BioSciences
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of exoIL-12 in cutaneous T-cell lymphoma (CTCL), sponsored by Codiak BioSciences. Primary endpoints: Safety and Tolerability up to 2 years, Pharmacokinetics up to 2 years and 1 more. Started Sep 2021; status: terminated.
02
Drugs
exoIL-12
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT05156229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156229.